Rezolute's High-Stakes Gamble After a Pivotal Trial Misses its Mark

REDWOOD CITY, CA – February 12, 2026 – Rezolute, Inc. finds itself at a critical crossroads, navigating the fallout from a major clinical trial failure while simultaneously pointing to a separate, more promising path for its lead drug candidate, ersodetug. In its second-quarter fiscal 2026 update, the rare disease company confirmed it is preparing for a crucial meeting with the U.S. Food and Drug Administration (FDA) after its Phase 3 study in congenital hyperinsulinism (HI) failed to meet its goals, a setback that continues to reverberate through its financial and strategic planning.

The company reported a net loss of $22.8 million for the quarter ending December 31, 2025, a significant increase from the $15.7 million loss in the same period a year prior. The widening loss reflects rising operational costs, including severance payments from a workforce reduction in December, and underscores the financial pressures mounting on the firm. With its cash and investments down to $132.9 million, Rezolute is walking a financial tightrope as it seeks to salvage a future for a drug once seen as a potential breakthrough for a devastating rare disease.

A Trial's Troubling Outcome

The core of Rezolute's current challenge lies in the topline results from its sunRIZE study, announced in December 2025. The Phase 3 trial was designed to evaluate ersodetug, a monoclonal antibody, for treating congenital HI, a rare genetic disorder where excessive insulin production causes dangerously low blood sugar in infants and children. The study, however, did not meet its primary endpoint of reducing hypoglycemic events compared to a placebo.

According to the company, the failure was not due to a lack of drug activity but rather a "pronounced study effect." While ersodetug did reduce hypoglycemic events, participants in the placebo group also showed a substantial improvement. This phenomenon, where the intensive monitoring and care inherent in a clinical trial benefits all participants, masked the drug's statistical superiority.

The market's reaction to the December news was swift and brutal, with Rezolute's stock (Nasdaq: RZLT) plummeting nearly 90% in a single day, wiping out hundreds of millions in market capitalization and prompting investigations by several law firms.

Despite the statistical failure, Rezolute highlighted underlying data suggesting the drug was working as intended. Pharmacologic activity was observed through biomarker responses, and reductions in hypoglycemia were noted. Perhaps the most compelling testament to a perceived benefit came from the trial participants themselves: all 59 children who completed the study, including those on placebo, chose to enroll in an ongoing open-label extension where they receive ersodetug. The company noted that some of these children have since been able to discontinue other standard therapies.

The FDA Lifeline and a Path Forward

With the congenital HI program in jeopardy, Rezolute's focus now shifts to a critical, upcoming meeting with the FDA. The company plans to leverage its Breakthrough Therapy Designation—a status granted to expedite the development of drugs for serious conditions—to discuss the sunRIZE data and determine a viable regulatory path.

"This meeting will be pivotal in defining the future of the congenital HI program," one industry analyst commented, noting the high stakes involved.

While a trial failing its primary endpoint is a major blow, it is not always a death knell, particularly in rare diseases with high unmet need. The FDA has previously shown flexibility, approving drugs based on strong secondary endpoint data or compelling biomarker evidence. For congenital HI, the current standard of care is limited. The only FDA-approved drug, diazoxide, is ineffective for up to 60% of patients and carries significant side effects. For those who don't respond, the options are often off-label drug use or major surgery to remove part of the pancreas.

Patient advocacy groups emphasize the desperate need for better options. "Families live in constant fear of a hypoglycemic event that could cause irreversible brain damage," stated a representative from a leading congenital HI patient organization. "We need new, safer, and more effective treatments. Any drug that shows a real-world benefit, even if the trial metrics are complicated, deserves a thorough evaluation."

A Tale of Two Trials: Hope in Tumor HI

While the congenital HI program faces an uncertain future, Rezolute has another, more promising shot on goal with the same drug. The company is also developing ersodetug for tumor-induced hyperinsulinism, a related condition where tumors, such as insulinomas, cause life-threatening hypoglycemia.

Here, the outlook is considerably brighter. The ongoing Phase 3 upLIFT study is enrolling patients, with topline results expected in the second half of 2026. Crucially, the design of this trial was informed by highly successful results from a prior Expanded Access Program (EAP). Data from the first nine patients in that program showed that 75% of those dependent on intravenous dextrose were able to completely discontinue it after treatment with ersodetug.

This compelling evidence was strong enough for the FDA to not only grant Breakthrough Therapy Designation for this indication but also agree to a streamlined, single-arm, open-label study design. This trial structure, which lacks a placebo control, suggests a high degree of confidence from the regulator in the drug's potential effect, based on the EAP data. For investors and patients, the upLIFT study now represents the company's clearest and most promising path to market.

Navigating the Financial Squeeze

The diverging clinical paths are set against a backdrop of tightening finances. The company's cash, cash equivalents, and marketable securities stood at $132.9 million on December 31, 2025, down from $167.9 million six months earlier. The quarterly burn rate, driven by research and administrative expenses, has put the company's financial runway in sharp focus. Following the sunRIZE trial failure, Rezolute moved to conserve cash by reducing its workforce by 29 employees in December, incurring $1.5 million in one-time severance costs that contributed to the quarter's increased expenses.

Management stated its current cash is sufficient to fund operations for "at least 12 months," a period that should see it through the upcoming FDA meeting and, critically, past the expected data release for the upLIFT tumor HI trial.

Analyst sentiment remains divided. In the wake of the sunRIZE failure, several firms slashed their price targets on RZLT stock, with some downgrading their ratings. However, others have maintained "Buy" ratings, pointing to the potential of the tumor HI program and the possibility of salvaging the congenital HI indication. The stock's modest rebound following the latest earnings report suggests some investors believe the worst of the bad news is priced in, with attention now fixed on the potential of the upLIFT trial and the outcome of the FDA meeting. Rezolute is now a company with a dual destiny, fighting to reclaim a future for one program while banking on the success of another.